(DNTH)

Role: EVP, Head of R&D
Signature: /s/ Adam Veness, as attorney-in-fact for Simrat Randhawa
Issuer symbol: DNTH
Transactions as of: 13 Nov 2025
Net transactions value: -$4,381,751
Form type: 4
Filing time: 14 Nov 2025, 21:00:06 UTC
Previous filing: 25 Sep 2025
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Randhawa Simrat	EVP, Head of R&D	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK	/s/ Adam Veness, as attorney-in-fact for Simrat Randhawa	14 Nov 2025	0001992260

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNTH	Common Stock	Options Exercise	$708,774	+83,978	+2099%	$8.44	87,978	13 Nov 2025	Direct	F1
transaction	DNTH	Common Stock	Options Exercise	$63,099	+3,529	+4%	$17.88	91,507	13 Nov 2025	Direct	F1
transaction	DNTH	Common Stock	Sale	$936,743	-26,166	-29%	$35.80	65,341	13 Nov 2025	Direct	F1, F2
transaction	DNTH	Common Stock	Sale	$1,584,016	-42,765	-65%	$37.04	22,576	13 Nov 2025	Direct	F1, F3
transaction	DNTH	Common Stock	Sale	$700,687	-18,576	-82%	$37.72	4,000	13 Nov 2025	Direct	F1, F4
transaction	DNTH	Common Stock	Options Exercise	$720,332	+40,287	+1007%	$17.88	44,287	14 Nov 2025	Direct	F1
transaction	DNTH	Common Stock	Options Exercise	$816,244	+37,494	+85%	$21.77	81,781	14 Nov 2025	Direct	F1
transaction	DNTH	Common Stock	Options Exercise	$689,688	+31,250	+38%	$22.07	113,031	14 Nov 2025	Direct	F1
transaction	DNTH	Common Stock	Sale	$4,158,442	-109,031	-96%	$38.14	4,000	14 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNTH	Stock Option (Right to Buy)	Options Exercise	$0	-83,978	-88%	$0.000000	11,996	13 Nov 2025	Common Stock	83,978	$8.44	Direct	F1, F5
transaction	DNTH	Stock Option (Right to Buy)	Options Exercise	$0	-3,529	-2.9%	$0.000000	116,471	13 Nov 2025	Common Stock	3,529	$17.88	Direct	F1, F6
transaction	DNTH	Stock Option (Right to Buy)	Options Exercise	$0	-40,287	-35%	$0.000000	76,184	14 Nov 2025	Common Stock	40,287	$17.88	Direct	F1, F6
transaction	DNTH	Stock Option (Right to Buy)	Options Exercise	$0	-37,494	-37%	$0.000000	62,506	14 Nov 2025	Common Stock	37,494	$21.77	Direct	F1, F7
transaction	DNTH	Stock Option (Right to Buy)	Options Exercise	$0	-31,250	-21%	$0.000000	118,750	14 Nov 2025	Common Stock	31,250	$22.07	Direct	F1, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
F2	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.48 to $37.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.48 to $38.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5	The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F6	The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F7	The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F8	The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.